Capricor Therapeutics stock rose nearly 5% after trial data showed Deramiocel stabilized heart function in patients ahead of a November FDA decision.
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
Waconzy News Desk1 min read · 22 words0 comments
No reactions yet
Request a correctionGet the Brief
The top of the wire and the Insider Watch summary, sent when there is something worth your time.
Community takes
None yetSign in to post a take, a question or a thread.
Sign in to postNo takes on this story yet. Post the first one above.
Join the discussion
Sign in to comment, vote and follow the stories you care about.
Sign in to commentNo comments yet. Be the first to add context to this story.